Endothelial TFEB signaling-mediated autophagic disturbance initiates microglial activation and cognitive dysfunction

Yaping Lu1, Xiang Chen2, Xiuxiu Liu2

  • 1Department of Physiology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu, China.

Autophagy
|January 2, 2023
PubMed

Insights

Bortezomib chemotherapy causes cognitive impairment by activating microglia. Enhancing TFEB nuclear translocation with digoxin may reverse this, offering a new therapeutic strategy for chemotherapy-induced cognitive dysfunction.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapy-induced cognitive impairment is a significant clinical challenge.
  • The underlying molecular mechanisms of chemotherapy-induced cognitive dysfunction remain poorly understood.
  • Bortezomib (BTZ) is a chemotherapy agent known to cause side effects, including potential cognitive impairment.

Purpose of the Study:

  • To investigate the molecular pathways linking bortezomib exposure to cognitive impairment.
  • To identify potential therapeutic targets for mitigating chemotherapy-induced cognitive dysfunction.
  • To explore the role of transcription factor EB (TFEB) in bortezomib-mediated neurotoxicity.

Main Methods:

  • Utilized mouse models and cell cultures (human brain microvascular endothelial cells) exposed to bortezomib.
  • Assessed microglia activation, cognitive function (novel object recognition, object location tests), and molecular markers including TFEB nuclear translocation, STAT3 phosphorylation, and IL23A expression.
  • Investigated the effects of pharmacological enhancement of TFEB nuclear translocation using digoxin and genetic ablation of IL23A.

Main Results:

  • Bortezomib exposure induced microglia activation and cognitive impairment.
  • This was associated with decreased TFEB nuclear translocation, increased STAT3 phosphorylation, and elevated IL23A expression.
  • Digoxin treatment restored lysosomal function and reduced IL23A secretion, ameliorating cognitive deficits.
  • Brain endothelial-specific ablation of IL23A also reduced microglia activation and cognitive dysfunction.

Conclusions:

  • The endothelial TFEB-STAT3-IL23A axis is a critical pathway in bortezomib-induced cognitive impairment.
  • Reversing TFEB nuclear translocation represents a potential therapeutic strategy to prevent cognitive dysfunction during bortezomib treatment.

Related Concept Videos

Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...